Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study-Reference-Cited by-同舟云学术

Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study

Published:2022-09-23 Issue:12 Volume:101 Page:2719-2729
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Najima Yuho^ORCID,Tachibana Takayoshi,Takeda Yusuke,Koda Yuya,Aoyama Yasuhisa,Toya Takashi,Igarashi Aiko,Tanaka Masatsugu,Sakaida Emiko,Abe Ryohei,Onizuka Makoto,Kobayashi Takeshi,Doki Noriko,Ohashi Kazuteru,Kanamori Heiwa,Ishizaki Takuma,Yokota Akira,Morita Satoshi,Okamoto Shinichiro,Kanda Yoshinobu

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-022-04981-x.pdf

Reference32 articles.

1. Konuma T, Shimomura Y, Ozawa Y, Ueda Y, Uchida N, Onizuka M, Akiyama M, Mori T, Nakamae H, Ohno Y, Shiratori S, Onishi Y, Kanda Y, Fukuda T, Atsuta Y, Ishiyama K (2019) Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: a propensity score matched analysis. Hematol Oncol 37:85–95

2. Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D (2009) Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant 15:30–38

3. Mielcarek M, Storer BE, Flowers ME, Storb R, Sandmaier BM, Martin PJ (2007) Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 13:1160–1168

4. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232

5. de Lima M, Giralt S, Thall PF, de Padua SL, Jones RB, Komanduri K, Braun TM, Nguyen HQ, Champlin R, Garcia-Manero G (2010) Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 116:5420–5431

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. WT1 gene mutations impact post-transplant relapse in myelodysplastic syndrome with excess blasts 2 patients;Annals of Hematology;2024-07-06

2. Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies;Cytometry Part B: Clinical Cytometry;2024-01

3. A pharmacodynamic assay to monitor treatment with the hypomethylating cytosine analogs, decitabine and azacitidine;Methods in Cell Biology;2024

4. Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplantation;Transplantation and Cellular Therapy;2023-11

5. Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia;Best Practice & Research Clinical Haematology;2023-06